Senescence

Big pharma enters senolytic drug discovery programme

Japanese pharma Taisho teams with Insilico to discover novel molecules that will tackle aging. It was announced today that Taisho Pharmaceutical and Insilico Medicine have...

Nutraceuticals to mitigate immunosenescence and aging

Mounting evidence shows that among other health benefits, nutraceuticals can promote healthy aging. Accumulation of senescent cells in tissues and organs is a hallmark...

Exclusive video interview with Dave Asprey

We talk supplementation, neurotech, mitochondrial dysfunction, clinical scale-ups, COVID and CGM with Longevity legend: Dave Asprey Ahead of Revolution Against Aging and Death conference, which...

Telomere length variations in tissue have implications for Longevity

Scientists from the University of Chicago Medical Center show that the rate of telomere shortening during aging is determined by the tissue type, genetic...

The Faloon regimen: we connect with a RAADfest icon

Bill Faloon is pushing Longevity forward to "enable biological senescence to go in reverse". Totally RAADfest: Ahead of this week's Revolution Against Aging and Death...

The interferons are coming to senolytic aging therapies

A new report suggests that studying the relationship between interferons and senescence could be key to developing new anti-aging therapies.  There are some things which...

Senolytics applied to the rejuvenation of organs

Scientists from Brigham & Women’s Hospital show that senolytics can rejuvenate organs from elderly donors by eliminating senescent cells and alleviating age-associated inflammation. In a...

Targeting senescent cells to extend lifespan

Although our understanding of the mechanisms underlying aging is limited, recent findings from animal studies indicate that targeting cellular senescence in vivo may prevent...

Reversing damage to rewind the aging clock

Emerging evidence suggests that targeting systemic damage may hold promise for rejuvenation and the treatment of age-related disorders. It has become evident that accumulation of...

Senolytics research shows Longevity progress

Senolytic research in humans may be in its infancy, but there is reason for cautious optimism. Last week we reported on biotech company UNITY's decision...

Elysium publishes positive results from two studies for Basis

Encouraging news from Elysium Health illustrates that the Longevity supplements market is building clinical and commercial traction. In December 2019, Elysium announced a $40m Series...

Taking NAD+ to the next level

Nuchido’s systems pharmacology approach yields NAD+ supplement that claims to boost levels by 242%!    A new player in the NAD+ supplement market has arrived...

UNITY cuts lead program after clinical trial fail

Company to focus on ophthalmologic and neurologic programs as Phase 2 knee osteoarthritis clinical study fails to meet primary endpoint. Senolytic therapy developer UNITY...

Juvenescence (2): “It’s all about prevention, and that’s incredibly disruptive”

Juvenescence's Greg Bailey on democratising healthcare, paradigm shifts and disruptive technologies. Yesterday we published the first part of our interview with Greg Bailey, CEO of...

Juvenescence (1): from strength to strength in R&D and investment firepower

Juvenescence's Greg Bailey on transformative scientific opportunities, immuno-resilience, modifying aging and funding. Continuing our series of interviews with our Advisory Panel members, we spoke to Greg...

Rejuvenation Roadmap charts life extension progress

We take a trip down Lifespan.io's Rejuvenation Roadmap – and it's a journey towards Longevity progress. Lifespan.io is a US-based non-profit organisation that seeks to...

Longevity therapies delivered through skin is a topical issue

Non-invasive therapy that comes in a bottle could be the Longevity crème de la crème. Therapeutic substances like arnica, turmeric and witch hazel have been...

Evidence for tenth hallmark of aging increases with new paper

Is ten the new nine? Additional research adds weight to the argument that extracellular matrix stiffening should be considered the tenth hallmark of aging. Since...

SENISCA seeks funding for senescence reversal

University of Exeter spinout raising seed investment as it targets aging aesthetics and age-related disease with ground-breaking rejuvenation technology. Deep in the labs at the...

de Magalhães interview: “Still lots of work to do”

Professor João Pedro de Magalhães on different areas of Longevity. Continuing our series of interviews with our Advisory Panel members, we caught up with João Pedro...

Latest articles

Epigenetic regulation of protein homeostasis following DNA damage

Recent study identifies critical regulator of protein biosynthesis recovery and homeostasis required for Longevity. Unresolved DNA damage caused by intrinsic and environmental factors accumulates during...

Deep Longevity and Longenesis collaborate to clock aging

Start the clock to stop the clock – centralised data will aid Longevity research.  Deep Longevity, which engages in the development of explainable AI systems...

Big Brother approach to accelerate preclinical studies

Tracked.bio develops AI computer vision system that tracks flies and mice to reduce man-hours and increase data collected in Longevity studies. A Danish start-up aims...

Astellas to acquire iota Biosciences

Following an R&D collaboration that began last year, Japanese pharma Astellas has announced it will acquire bioelectronics firm iota in $304m deal. Last year's R&D...